Would you offer adjuvant abemaciclib to node-positive patients with low ER expression?

Topics: Breast Cancer • Medical Oncology • HR+ • Breast Cancer, Non-metastatic

For instance, ER/PR >1% but <10% and Ki67 >50%

Answer from: Medical Oncologist at Academic Institution

This tumor is likely biologically similar to a triple negative tumor, thus it is not surprising that it has a high Ki67. More information is really needed on if/what neoadjuvant therapy this patient received to better answer this question.Although both KEYNOTE-522 and monarchE use the ASCO-CAP guide...

Comments

Medical Oncologist at Harvard Medical School
I fully agree--I would consider this patient a can...

Medical Oncologist at NYU Winthrop Hospital
KEYNOTE-522 - Only in triple negative patients. I...

Answer from: Medical Oncologist at Community Practice

The monarchE trial enrolled patients with ER or PR positive tumors by IHC according to ASCO 2010 guidelines. Based on those, this patient would qualify as HR+, node positive with a Ki67 >20%, and would consider offering adjuvant abemaciclib.

Answer from: Medical Oncologist at Community Practice

No.

Related Questions